Cost-Effectiveness Thresholds: the Past, the Present and the Future

被引:0
|
作者
Praveen Thokala
Jessica Ochalek
Ashley A. Leech
Thaison Tong
机构
[1] University of Sheffield,Health Economics and Decision Science, School of Health and Related Research
[2] University of York,Centre for Health Economics
[3] Center for the Evaluation of Value and Risk in Health (CEVR),undefined
[4] Tufts Medical Center,undefined
来源
PharmacoEconomics | 2018年 / 36卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Cost-effectiveness (CE) thresholds are being discussed more frequently and there have been many new developments in this area; however, there is a lack of understanding about what thresholds mean and their implications. This paper provides an overview of the CE threshold literature. First, the meaning of a CE threshold and the key assumptions involved (perfect divisibility, marginal increments in budget, etc.) are highlighted using a hypothetical example, and the use of historic/heuristic estimates of the threshold is noted along with their limitations. Recent endeavours to estimate the empirical value of the thresholds, both from the supply side and the demand side, are then presented. The impact on CE thresholds of future directions for the field, such as thresholds across sectors and the incorporation of multiple criteria beyond quality-adjusted life-years as a measure of ‘value’, are highlighted. Finally, a number of common issues and misconceptions associated with CE thresholds are addressed.
引用
收藏
页码:509 / 522
页数:13
相关论文
共 50 条
  • [1] Cost-Effectiveness Thresholds: the Past, the Present and the Future
    Thokala, Praveen
    Ochalek, Jessica
    Leech, Ashley A.
    Tong, Thaison
    [J]. PHARMACOECONOMICS, 2018, 36 (05) : 509 - 522
  • [2] Future Costs in Cost-Effectiveness Analyses: Past, Present, Future
    Linda M. de Vries
    Pieter H. M. van Baal
    Werner B. F. Brouwer
    [J]. PharmacoEconomics, 2019, 37 : 119 - 130
  • [3] Future Costs in Cost-Effectiveness Analyses: Past, Present, Future
    de Vries, Linda M.
    van Baal, Pieter H. M.
    Brouwer, Werner B. F.
    [J]. PHARMACOECONOMICS, 2019, 37 (02) : 119 - 130
  • [4] Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future
    Harris, Marianne
    Nosyk, Bohdan
    Harrigan, Richard
    Lima, Viviane Dias
    Cohen, Calvin
    Montaner, Julio
    [J]. AIDS RESEARCH AND TREATMENT, 2012, 2012
  • [5] Challenges of calculating cost-effectiveness thresholds
    Paternina-Caicedo, Angel
    Hoz-Restrepo, Fernando De la
    Alvis-Guzman, Nelson
    [J]. LANCET GLOBAL HEALTH, 2023, 11 (10): : E1509 - E1509
  • [6] Cost-effectiveness thresholds: a comment on the commentaries
    Culyer, Anthony J.
    [J]. HEALTH ECONOMICS POLICY AND LAW, 2016, 11 (04) : 445 - 447
  • [7] Cost-effectiveness thresholds: pros and cons
    Bertram, Melanie Y.
    Lauer, Jeremy A.
    De Joncheere, Kees
    Edejer, Tessa
    Hutubessy, Raymond
    Kieny, Marie-Paule
    Hill, Suzanne R.
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2016, 94 (12) : 925 - 930
  • [8] Costs and thresholds in cost-effectiveness analysis
    Sartore, M. E.
    Kamal, K. M.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (10) : 1455 - 1456
  • [9] COST-EFFECTIVENESS THRESHOLDS: REVIEW OF METHODS
    Santos, A. S.
    Guerra-Junior, A. A.
    Brandao, C. M.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A860 - A860
  • [10] COST: Past, present, future
    Fedi, F
    [J]. PROCEEDINGS OF THE EURO BERRY SYMPOSIUM - COST 836 FINAL WORSKHOP, 2004, (649): : 21 - 24